Back to Top Skip to main content
Alert Arrow ALERT!!

There are emergency procedures in place for parts of world due to weather.

Get the latest information on emergency prescription refills and PCM referral waivers. 

Meeting Date: May 14-15, 2014

Download the UF BPA TemplateDownload the UF VARR Template

Information for Pharmaceutical Manufacturers

Price & Refund Quotes Due Date  Posted Date  Drug Class/Subclass/Route/Newly Approved Drugs Utilization  UF BPA Appendix  UF VARR Appendix
April 7, 2014 March 6, 2014 Class: Osteoporosis Agents
Subclass: Bisphosphonates
Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Class: Nasal Allergy Agents Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Class: Pulmonary-1 Agents
Subclass: Corticosteroids
Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Myrbetriq Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Farziga Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Sovaldi Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Uceris Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Eliquis Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Zorvolex Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Quillivant XR Industry Report UF BPA Appendix UF VARR Appendix
April 7, 2014 March 6, 2014 Arcapta Neohaler Industry Report UF BPA Appendix UF VARR Appendix

Clinical Presentations

P&T Meeting  Drug Class/Subclass/Route Utilization Notes 
August 13-14, 2014 PEC Class: Targeted Immunomodulatory Biologics Final Report Clinical Presentations Only
August 13-14, 2014 PEC Class: Multiple Sclerosis Agents Final Report Clinical Presentations Only
August 13-14, 2014

PEC Class: Narcotic Analgesics and Combinations

PEC Subclass: Fentanyl

Coming Soon Clinical Presentations Only

Teleconference Notice

May 2014 DoD P&T Meeting Reviews

The teleconference will be held March 17, 2014, 10:30 AM Central Time.

The teleconference will review the quoting process and to address industry questions about these reviews. Interested manufacturers must register by submitting participant's name, company name, and the drug class your product is assigned and any advance questions via email or call 1-303-676-3754 no later than Mary 14, 2014. Advance questions will be addressed during the teleconference.

The call-in number and a pre-conference agenda will be emailed to all registered participants. A summary of the teleconference, to include all questions and answers, will be posted at this site following the teleconference.

Bid Submission Steps:

Step 1: Download Utilization.

Step 2: Download and complete the UF BPA and VARR template and applicable appendix.

Step 3: Send original signed quotes to:

Pharmacy Contracting Officer/COD
DoD Uniform Formulary BPA
Defense Health Agency
16401 East Centretech Parkway
Aurora, CO 80011-9043

UF BPA Quotes:

Pharmaceutical companies may submit UF BPA price quotes for pharmaceutical agents in the classes under review that will be used by the DoD P&T Committee as the cost to the government portion of its relative cost effectiveness considerations under 32 CFR 199.21.

The original signed UF BPA quote and e-mail containing the duplicate in Adobe PDF file format must be received by 1:00 PM EST of the date specified above. Quotes received after the deadline may be rejected by the Contracting Officer. All original quotes must contain original signatures. The original signed quote and the electronic duplicate must be identical in every aspect.

The establishment of a UF BPA with a pharmaceutical company for a generic (multi-source) pharmaceutical agent does not establish that pharmaceutical company as the sole source of supply for the pharmaceutical agent. However, in the event of existing Joint DoD/VA contracts, UF BPA quotes will not be accepted for generic (multi-source) pharmaceutical agents.

UF VARR Quotes:

Pharmaceutical companies may submit Uniform Formulary Voluntary Agreements for TRICARE Retail Pharmacy Refunds (UF VARR) quotes for pharmaceutical agents in the classes under review that will be used by the DoD P&T Committee as the cost to the government portion of its relative cost effectiveness considerations under 32 CFR 199.21.

The original signed UF VARR quote and e-mail containing the duplicate in Adobe PDF file format must be received by 1:00 PM EST of the date specified above. Quotes received after the deadline may be rejected by the Contracting Officer. All original quotes must contain original signatures. The original signed quote and the electronic duplicate must be identical in every aspect.

UF VARR quotes will not be accepted for generic (multi-source) pharmaceutical agents.

NOTICE

For some drug classes, DoD may require companies to submit multiple price and refund quotes contingent upon the number of agents selected to the Uniform Formulary (UF) or Basic Core FormularyThe Basic Core Formulary (BCF) is a list of medications required to be on formulary at all full-service military treatment facilities (MTFs). BCF medications are intended to meet the majority of the primary care needs of DoD beneficiaries.Basic Core Formulary (BCF) as defined by the government. Please read carefully the information about submitting multiple quotes in the UF Price and Refund Information, the applicable 'Drug Class Pages' that are linked to the Drug Classes Under Review page, the UF BPA Price Quote Template, and the UF VARR Refund Quote Template. Please use the contact Information below for additional questions.

General (all reviews)

The DoD reserves the right to exclude specific formulations or NDCs of a given drug from a submitted UF BPA and/or UF VARR based on recommendations from the P&T Committee and decision of the Director, DHA.

For additional questions, please call 1-303-676-3529.

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.